Journal of Clinical Oncology
Articles in this Issue
A phase 2 trial of TAS-102 with or without celecoxib in ctDNA-defined minimal residual disease (MRD) in colorectal cancer after completion of adjuvant chemotherapy.
TPS270 Background: Multiple studies demonstrate that circulating tumor DNA (ctDNA) captures radiographically occult microm...
Real-world prospective comparison of sorafenib and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A multicenter study in Japan (KSCC HAMRET).
562 Background: Systemic therapy for hepatocellular carcinoma (HCC) has rapidly evolved, and immune checkpoint inhibitor (...
How collaboration between surgeons and medical oncologists affects outcomes for patients with pancreatic cancer.
694 Background: The number of patients shared between medical providers can serve as a marker of collaboration, which may...
Impact of heterozygous UGT1A1*28 genotype on toxicity, dose-intensity and treatment compliance in pancreatic cancer patients receiving FOLFIRINOX/mFOLFIRINOX.
698 Background: Pancreatic cancer remains the deadliest solid tumor because of late-stage presentation, intrinsic chemores...
Outcomes of carcinoid syndrome in small versus large intestinal neuroendocrine tumors.
620 Background: Carcinoid syndrome (CS) most commonly arises from small intestinal neuroendocrine tumors (NETs) due to the...
Secondary primary malignancy (SPM) in localized gastrointestinal (GI) cancer: A national database study.
529 Background: With improvement in survival in patients with early GI cancers, there is a perceived increased risk of SPM...
Oncologic outcomes in patients undergoing robotic esophagectomy.
328 Background: Esophageal cancer (EC) is associated with significant mortality worldwide. Robotic assisted minimally inva...
Key lessons from phase I trials in gastroesophageal cancer treated in Gustave Roussy Cancer Center.
321 Background: Gastroesophageal cancer (GEC) treatment has advanced in recent years with the introduction of targeted the...
Comparative efficacy and safety of microwave ablation versus open surgical resection in colorectal liver metastases: A systematic review and meta-analysis.
144 Background: Colorectal liver metastases (CRLM) represent a major therapeutic challenge in colorectal cancer. While ope...
A multi-agent system for automated identification of competitive clinical trials in colorectal cancer.
193 Background: Understanding the competitive clinical trial landscape is essential for successful trial planning, particu...
Clinical determinants of survival and a predictive immune biomarker for immunotherapy in fibrolamellar carcinoma: A comprehensive institutional analysis.
552 Background: Fibrolamellar carcinoma (FLC) is a rare liver malignancy primarily in adolescents / young adults with limi...
Tolerability and outcomes after neoadjuvant and definitive radiation of elderly patients with localized pancreatic cancer.
664 Background: Multimodal therapy for pancreatic cancer (PC) may be challenging in older adults with comorbidities or lim...
Diffuse idiopathic skeletal hyperostosis (DISH) and gastrointestinal system cancer: A Mayo Clinic platform study.
851 Background: Diffuse idiopathic skeletal hyperostosis (DISH) has been associated with increased risk of vertebral fract...
Efficacy and safety of pralsetinib in <i>RET</i> fusion-positive solid tumors: Data from the TAPISTRY trial.
184 Background: Pralsetinib is an oral tyrosine kinase inhibitor that selectively and potently targets oncogenic RET fusio...
Anastomotic leak and oncologic outcomes after colorectal cancer resection: A real-world analysis.
71 Background: Anastomotic leak (AL) is a serious complication after colorectal cancer resection and may worsen outcomes v...
FIT as a cornerstone of CRC screening: Optimization for advanced neoplasia.
29 Background: Colorectal cancer (CRC) remains as a leading cause of cancer-related morbidity as well as mortality worldwi...
The peritoneal immune landscape in gastrointestinal peritoneal metastasis patients and the impact of intraperitoneal paclitaxel.
195 Background: Peritoneal metastasis (PM) from gastrointestinal (GI) malignancies respond poorly to traditional systemic...
CRUK: Phase II trial of ginisortamab with (1) 1st-line gemcitabine + nab-paclitaxel (AG) or (2) MEK inhibitor as maintenance therapy in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
TPS793 Background: mPDAC has a poor prognosis with a median overall survival < 1 year with chemotherapy. Gremlin-1, sec...
Use of serial ctDNA dynamics to predict clinical outcomes in metastatic and locally advanced PDAC: A systematic review.
785 Background: Circulating tumor DNA (ctDNA) is a potential prognostic marker detectable in a substantial proportion of p...
Trifluridine-tipiracil versus radioembolization for patients with refractory colorectal liver metastases: A real-world data analysis.
160 Background: Liver-directed and systemic therapies are available for refractory colorectal liver metastases (CRLM), but...
Pembrolizumab in combination with chemotherapy as conversion therapy for esophageal squamous cell carcinoma with cervical lymph node metastasis: A single-center, prospective, single-arm, open-label, real-world study.
386 Background: The combination of immunotherapy and chemotherapy has become the standard first-line treatment for advance...
Age-associated mutation patterns and a potential therapeutic opportunity in early-onset colorectal cancer.
197 Background: Colorectal cancer (CRC) is increasingly diagnosed in younger adults, with evidence that early-onset cases...
Clonal hematopoiesis of indeterminate potential: A potential risk factor for GI malignancies.
591 Background: Clonal hematopoiesis of indeterminate potential (CHIP) occurs when a hematopoietic stem cell undergoes clo...
Trends in brachytherapy use and survival outcomes in rectal adenocarcinoma: Insights from the National Cancer Database.
168 Background: In the U.S. alone, approximately 45000 people are diagnosed yearly with rectal adenocarcinoma. Surgical re...
Clinical understaging in early gastric cancer: A common and significant problem.
333 Background: A portion of clinical stage I gastric cancer (GC) patients who undergo upfront surgery are understaged pre...